Dr. Fizazi discusses potential of darolutamide-based triplet regimen for metastatic hormone-sensitive prostate cancer
“Obviously, patients benefit [from this regimen]. Not only can they enjoy longer life, but also their cancer is pretty much under control for a longer time, which is great,” says Karim Fizazi, MD, PhD
In this episode, Urology Times® Assistant Editor Janelle Hart spoke with Karim Fizazi, MD, PhD, about results from a game-changing study that was presented at the 2022 ASCO Genitourinary Cancers Symposium. The phase 3 ARASENS trial showed that a darolutamide-based triplet regimen improved overall survival in patients with metastatic hormone-sensitive prostate cancer. Fizazi is a medical oncologist and head of the department of cancer medicine at the Institute of Gustave Roussy, and professor of oncology at the University of Paris Sud in Villejuif, France.
UGN-102 reaches nearly 80% complete response rate in low-grade intermediate-risk NMIBC
November 30th 2023Primary chemoablative therapy with the mitomycin-containing reverse thermal gel UGN-102 induced complete responses in nearly 4 out of 5 patients with low-grade intermediate-risk non–muscle-invasive bladder cancer.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
